Casdin Capital LLC Takes $8.22 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Casdin Capital LLC acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $8,215,000. Agios Pharmaceuticals accounts for 0.5% of Casdin Capital LLC’s investment portfolio, making the stock its 24th largest position. Casdin Capital LLC owned about 0.44% of Agios Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at $33,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $53,000. Sterling Capital Management LLC increased its holdings in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 2,338 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AGIO shares. Scotiabank cut their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research report on Friday. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 1st. Finally, HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $29.97 on Tuesday. The firm has a market cap of $1.74 billion, a P/E ratio of 2.64 and a beta of 0.83. The stock’s 50-day moving average is $29.72 and its two-hundred day moving average is $37.65. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. On average, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.93% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.